Franciely Bueno Wiginesk

Franciely Bueno Wiginesk

Auto-generated profile, based on publicly available information

Franciely Bueno Wiginesk

Instituto de Cardiologia Campo Grande, Campo Grande, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2024 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
FNFrank Nunes
Frank Nunes
BGBreno Moreno de Gusmão
Breno Moreno de Gusmão
FWFranciely Bueno Wiginesk
Franciely Bueno Wiginesk
EMEuler Manenti
Euler Manenti
JSJuliana Soares
Juliana Soares
AMAriane Vieira Scarlatelli Macedo
Ariane Vieira Scarlatelli Macedo
Chimeric antigen receptor T-cell therapy represents an innovative approach to immunotherapy and currently stands out, particularly for oncohematological patients refractory to traditional treatments. Ongoing trials are further expanding its clinical use for new oncological and non-oncological indications, potentially leading to newer treatment options soon. This new approach, however, also presents challenges, including cardiovascular toxicity. Little is reported in pivotal studies, and some recent retrospective observations suggest a non-negligible incidence of side effects with presentation ranging from mild adverse cardiovascular events to fatal complications in which, in most cases, there is a direct or indirect association with cytokine release syndrome. In this literature review, the hypotheses of an important interface between cytokine release syndrome and cardiotoxicity by chimeric antigen receptor T-cell therapy will be addressed, as will current knowledge about risk factors for cardiotoxicity and recommendations for pre-therapy evaluation, post-infusion monitoring and clinical management of these complications.